| Mr Andrew Kempe Midgley, CAA | |
|
2500 Metrohealth Dr, Cleveland, OH 44109-1900 | |
| (216) 778-4801 | |
| Not Available |
| Full Name | Mr Andrew Kempe Midgley |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology Assistant |
| Experience | 3 Years |
| Location | 2500 Metrohealth Dr, Cleveland, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558937243 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | (* (Not Available)) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Metrohealth System | Cleveland, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Metrohealth System | 8628982949 | 1026 |
News Archive
The presidents of Technische Universität Darmstadt, Johannes Gutenberg University Mainz, and Goethe University Frankfurt have signed a cross-border framework agreement intended to promote further collaboration between the three universities.
"This week, the Global Alliance for Vaccines and Immunization (GAVI) is holding a forum in Dar es Salaam, Tanzania," Guardian health editor Sarah Boseley writes in her "Global Health Blog," noting, "Invited are 700 experts from all the organizations and countries GAVI works with, funding immunization programs across the globe and in some of the poorest places on the planet."
"For the most part, doctor fees are a mystery. If people see a doctor who is part of their insurance network, they are responsible only for deductibles and co-payments, and the price the health insurer pays is often a secret," The New York Times reports. "And if people see a doctor outside their network, they usually have no idea what the charge will be - even though they are responsible for most of it - until the bill comes."
MAP Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatment of migraine. The Company announced in May 2009 that the efficacy portion of its Phase 3 FREEDOM-301 clinical study of LEVADEX met all four primary endpoints. The Company had previously anticipated initiating a second pivotal efficacy study in the first quarter of 2010.
For Michigan State University's Felicia Wu, the surprise isn't that people who work with livestock are at higher risk of picking up antibiotic-resistant bacteria, but instead how much higher their risk levels are.
› Verified 9 days ago
| Entity Name | The Metrohealth System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053353896 PECOS PAC ID: 8628982949 Enrollment ID: O20031119000355 |
News Archive
The presidents of Technische Universität Darmstadt, Johannes Gutenberg University Mainz, and Goethe University Frankfurt have signed a cross-border framework agreement intended to promote further collaboration between the three universities.
"This week, the Global Alliance for Vaccines and Immunization (GAVI) is holding a forum in Dar es Salaam, Tanzania," Guardian health editor Sarah Boseley writes in her "Global Health Blog," noting, "Invited are 700 experts from all the organizations and countries GAVI works with, funding immunization programs across the globe and in some of the poorest places on the planet."
"For the most part, doctor fees are a mystery. If people see a doctor who is part of their insurance network, they are responsible only for deductibles and co-payments, and the price the health insurer pays is often a secret," The New York Times reports. "And if people see a doctor outside their network, they usually have no idea what the charge will be - even though they are responsible for most of it - until the bill comes."
MAP Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatment of migraine. The Company announced in May 2009 that the efficacy portion of its Phase 3 FREEDOM-301 clinical study of LEVADEX met all four primary endpoints. The Company had previously anticipated initiating a second pivotal efficacy study in the first quarter of 2010.
For Michigan State University's Felicia Wu, the surprise isn't that people who work with livestock are at higher risk of picking up antibiotic-resistant bacteria, but instead how much higher their risk levels are.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Andrew Kempe Midgley, CAA 30800 Hilliard Blvd, Westlake, OH 44145-3724 Ph: (330) 507-5954 | Mr Andrew Kempe Midgley, CAA 2500 Metrohealth Dr, Cleveland, OH 44109-1900 Ph: (216) 778-4801 |
News Archive
The presidents of Technische Universität Darmstadt, Johannes Gutenberg University Mainz, and Goethe University Frankfurt have signed a cross-border framework agreement intended to promote further collaboration between the three universities.
"This week, the Global Alliance for Vaccines and Immunization (GAVI) is holding a forum in Dar es Salaam, Tanzania," Guardian health editor Sarah Boseley writes in her "Global Health Blog," noting, "Invited are 700 experts from all the organizations and countries GAVI works with, funding immunization programs across the globe and in some of the poorest places on the planet."
"For the most part, doctor fees are a mystery. If people see a doctor who is part of their insurance network, they are responsible only for deductibles and co-payments, and the price the health insurer pays is often a secret," The New York Times reports. "And if people see a doctor outside their network, they usually have no idea what the charge will be - even though they are responsible for most of it - until the bill comes."
MAP Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatment of migraine. The Company announced in May 2009 that the efficacy portion of its Phase 3 FREEDOM-301 clinical study of LEVADEX met all four primary endpoints. The Company had previously anticipated initiating a second pivotal efficacy study in the first quarter of 2010.
For Michigan State University's Felicia Wu, the surprise isn't that people who work with livestock are at higher risk of picking up antibiotic-resistant bacteria, but instead how much higher their risk levels are.
› Verified 9 days ago
Shannon Kelly, AA-C Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Olivia Kehoe, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 11100 Euclid Ave, Cleveland, OH 44106 Phone: 216-844-1000 | |
Brian Michael Wheatley, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Nicole M Moses, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Michael Marcotte, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Thomas Bruno, AA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 11100 Euclid Ave, Cleveland, OH 44106 Phone: 216-844-7330 | |
Gregory G Kychun, AA Anesthesiologist Assistant Medicare: Not Enrolled in Medicare Practice Location: 11100 Euclid Ave, Cleveland, OH 44106 Phone: 216-844-7330 |